Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
73 hedge funds and large institutions have $180M invested in Marinus Pharmaceuticals, Inc in 2018 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 19 increasing their positions, 9 reducing their positions, and 17 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 9
107% more capital invested
Capital invested by funds: $87M → $180M (+$92.7M)
82% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 17
73% more call options, than puts
Call options by funds: $5.01M | Put options by funds: $2.9M
22% more funds holding
Funds holding: 60 → 73 (+13)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11.2M |
| 2 |
TBC
Three Bays Capital
Boston,
Massachusetts
|
+$5.33M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.82M |
| 4 |
VMI
VHCP Management II
New York
|
+$1.91M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
-$4.84M |
| 2 |
Millennium Management
New York
|
-$2.34M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.25M |
| 4 |
Renaissance Technologies
New York
|
-$1.61M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.46M |
MRNS Hedge Fund Activity: Q2 2018 in Review
73 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2018, worth a combined $180M — up 107% from $87M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new MRNS positions and 17 closed out — a net gain of 14 holders — while 19 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $11.2M. The largest seller was GMT Capital, exiting entirely with an estimated $4.84M sold.
- 73 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2018, up from 60 in Q1 2018.
- Funds reported $180M of Marinus Pharmaceuticals, Inc stock for Q2 2018, up 107% quarter-over-quarter.
- 31 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2018 and 17 closed out, a net change of +14 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q2 2018 was BlackRock, an estimated $11.2M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q2 2018 was GMT Capital, an estimated $4.84M sold.
Based on aggregated 13F filings for Q2 2018.